Research Triangle Park drug discovery and development company SCYNEXIS has received a preclinical milestone payment for an undisclosed amount, resulting from a collaboration to discover and develop cancer drugs.
"We are pleased to celebrate success in reaching another milestone with our valued
partner, Merck," said Yves Ribeill, Ph.D., SCYNEXIS president and CEO. "This milestone provides further validation of our long-term relationship with Merck in a number of therapeutic areas through discovery research and innovation."
Since it was founded nine years ago, the privately held SCYNEXIS' research teams have integrated medicinal chemistry, advanced biological screening, computational chemistry, bioanalysis and analytical chemistry to find good drug candidates from its customers' arrays of possibilities.